QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.127258v1 323/2/665    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bhattacharya, A. Articles by Chaplan, S. R. Search for Related Content PubMed PubMed Citation Articles by Bhattacharya, A. Articles by Chaplan, S. R.

INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Pharmacology and Antitussive Efficacy of 4-(3-Trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic Acid (5-Trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a Transient Receptor Potential Vanilloid 1 Antagonist in Guinea Pigs

Departments of Pain and Related Disorders (A.B., B.P.S., N.N., H.A., M.P.M., A.E.D., A.D.W., S.R.C.), Neuroscience (D.M.S.), and Physiological Systems (N.P.S.), Johnson & Johnson Pharmaceutical Research & Development, LLC, San Diego, California

Transient receptor potential vanilloid 1 (TRPV1) plays an integral role in modulating the cough reflex, and it is an attractive antitussive drug target. The purpose of this study was to characterize a TRPV1 antagonist, 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), against the guinea pig TRPV1 receptor in vitro followed by a proof-of-principle study in an acid-induced model of cough. The affinity of JNJ17203212 for the recombinant guinea pig TRPV1 receptor was estimated by radioligand binding, and it was functionally characterized by antagonism of low-pH and capsaicin-induced activation of the ion channel (fluorometric imaging plate reader and electrophysiology). The nature of antagonism was further tested against the native channel in isolated guinea pig tracheal rings. Following pharmacokinetic characterization of JNJ17203212 in guinea pigs, pharmacodynamic and efficacy studies were undertaken to establish the antitussive efficacy of the TRPV1 antagonist. The pK_i of JNJ17203212 for recombinant guinea pig TRPV1 was 7.14 ± 0.06. JNJ17203212 inhibited both pH (pIC₅₀ of 7.23 ± 0.05) and capsaicin (pIC₅₀ of 6.32 ± 0.06)-induced channel activation. In whole-cell patch clamp, the pIC₅₀ for inhibition of guinea pig TRPV1 was 7.3 ± 0.01. JNJ17203212 demonstrated surmountable antagonism in isolated trachea, with a pK_B value of 6.2 ± 0.1. Intraperitoneal administration of 20 mg/kg JNJ17203212 achieved a maximal plasma exposure of 8.0 ± 0.4 µM, and it attenuated capsaicin evoked coughs with similar efficacy to codeine (25 mg/kg). Last, JNJ17203212 dose-dependently produced antitussive efficacy in citric acid-induced experimental cough in guinea pigs. Our data provide preclinical support for developing TRPV1 antagonists for the treatment of cough.

Address correspondence to: Dr. Anindya Bhattacharya, Johnson & Johnson Pharmaceutical Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121. E-mail: abhatta2{at}prdus.jnj.com

This article has been cited by other articles:

				Y. Niiyama, T. Kawamata, J. Yamamoto, S. Furuse, and A. Namiki SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain Br. J. Anaesth., February 1, 2009; 102(2): 251 - 258. [Abstract] [Full Text] [PDF]

				B. F. Bessac and S.-E. Jordt Breathtaking TRP Channels: TRPA1 and TRPV1 in Airway Chemosensation and Reflex Control Physiology, December 1, 2008; 23(6): 360 - 370. [Abstract] [Full Text] [PDF]